BR100 Increased By (0.34%)
BR30 Increased By (0.77%)
KSE100 Increased By (0.26%)
KSE30 Increased By (0.25%)
BECO 5.73 Increased By ▲ 0.34 (6.31%)
BML 57.30 Decreased By ▼ -0.16 (-0.28%)
BOP 36.77 Increased By ▲ 0.46 (1.27%)
CNERGY 8.39 Increased By ▲ 0.18 (2.19%)
DCL 12.04 Increased By ▲ 0.21 (1.78%)
FCCL 58.61 Decreased By ▼ -0.67 (-1.13%)
FCSC 5.01 No Change ▼ 0.00 (0%)
FFL 17.94 Increased By ▲ 0.09 (0.5%)
FNEL 1.26 No Change ▼ 0.00 (0%)
HUMNL 11.42 Decreased By ▼ -0.08 (-0.7%)
KEL 8.29 Decreased By ▼ -0.04 (-0.48%)
KOSM 6.62 Decreased By ▼ -0.01 (-0.15%)
MLCF 108.29 Increased By ▲ 0.86 (0.8%)
NBP 206.04 Increased By ▲ 1.03 (0.5%)
PACE 11.17 Increased By ▲ 0.07 (0.63%)
PAEL 45.35 Decreased By ▼ -0.07 (-0.15%)
PIAHCLA 30.77 Decreased By ▼ -0.99 (-3.12%)
PIBTL 19.06 Increased By ▲ 0.21 (1.11%)
PPL 245.95 Increased By ▲ 2.21 (0.91%)
PRL 36.08 Decreased By ▼ -0.16 (-0.44%)
PTC 72.36 Increased By ▲ 0.29 (0.4%)
SEARL 96.67 Increased By ▲ 2.09 (2.21%)
SSGC 31.67 Decreased By ▼ -0.18 (-0.57%)
TELE 9.27 Increased By ▲ 0.25 (2.77%)
THCCL 67.81 Decreased By ▼ -0.66 (-0.96%)
TPLP 11.23 Increased By ▲ 0.51 (4.76%)
TREET 25.89 No Change ▼ 0.00 (0%)
TRG 67.84 Increased By ▲ 3.53 (5.49%)
WAVES 10.98 Increased By ▲ 0.07 (0.64%)
WTL 1.28 Decreased By ▼ -0.01 (-0.78%)

Asad Umar launches phase 3 trials of coronavirus vaccine

  • Result is expected in 4 to 6 months, Umar said.
Published September 22, 2020 Updated September 22, 2020 12:39pm

Minister of Planning and Development Asad Umar announced on Tuesday that the phase three trials for a coronavirus vaccine in Pakistan has been launched.

In a tweet today, the minister said that phase three trials for the vaccine developed by a Chinese company, China’s CanSino Biologics has been launched. He further said a total of 40,000 people will participate in this trial in 7 countries.

Out of these 40,000 people, 8000 to 10000 will be Pakistanis, Umar said. "Initial results expected in 4 to 6 months," the minister added.

Addressing a presser today, the National Institute of Health Executive Director Major General Aamer Ikram said that the CanSino vaccine is based on recombinant technology. He said the vaccine will be administered to the volunteers after a medical examination.

He said although the NIH would follow up with them for 12 months, the results of the vaccine would be expected in three months.

Comments

Comments are closed for this article.